Overview

TAK-875 Glimepiride Drug-Interaction Study

Status:
Completed

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the pharmacokinetics and safety of TAK-875, once daily (QD), with and without glimepiride in participants with type 2 diabetes mellitus (T2DM).

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Glimepiride